$FMS News

Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Fresenius Medical Care Appoints Shervin J. Korangy As CEO Effective October 12; Shervin J. Korangy To Succeed Helen Giza

Fresenius Medical Care: Margin Expansion Supports The Story, But Growth Remains Limited

Fresenius Medical Care Refines China Strategy With Targeted Product Focus

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Fresenius Medical Care Adjusts China Commercial Strategy To Support Long-Term Growth And Strengthen Market Position Through More Localized Portfolio, Increased Commercialization Of Local Innovation And Focused Go-To-Market Plans

FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis

Fresenius Medical Care Publishes Global Study On Hemodiafiltration Associated With Lower Relative Risk Of Death From Conventional High-Flux Hemodialysis

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG 2026 Q2 - Results - Earnings Call Presentation

Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8

Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns

Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?

Fresenius Medical Care AG & Co. KGaA Q2 2026 Earnings Call Summary